P PRIMESTOCKFINDER.COM

SLD Shares Saluda Medical, Inc.

BUY ASX · ASX
$0.25 +0.00% Prices as of close 2026-10-27

Broker-backed turnaround potential and consumer healthcare exposure provide asymmetric speculative upside.

  • ▸Morgans speculative buy rating with $2.17 target
  • ▾Below 50-day MA (-41.63%)
  • ▾Near 52-week low (0% of range)

Trend: SLD is trading below the 50-day average (-36.90%), RSI 30 — oversold territory, with a 3-month return of -36.90%.

Valuation & quality: Saluda Medical, Inc. trades on forward P/E -0.7, price-to-book 0.86; fundamentals show net margin -165.9%, revenue growth 38.4% year on year.

Analyst consensus: 3 analysts have a mean 12-month price target of A$1.66 (+564% vs the last close; range A$1.30 – A$2.06), consensus rating “strong buy”.

Our screen: BUY (score 2) — Broker-backed turnaround potential and consumer healthcare exposure provide asymmetric speculative upside.

Computed from end-of-day data; not personal advice.

1.20 0.25 FebMarAprMayJunJulAugSepOct
Daily close, 2026-02-08 → 2026-10-27 (AUD). Range 0.25 – 1.20.
Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
-24.00%-24.10%-40.00%+27.80%-4.30%+6.80%-12.80%-36.60%
Market cap
$67.5M
P/E (ttm)
-0.6
Forward P/E
-0.7
EPS (ttm)
$-13.62
Price / book
0.86
Net margin
-165.9%
Revenue growth
38.4%
Revenue (ttm)
$90.2M
Free cash flow
$-60,362,876
Debt / equity
183%
52-wk range
$0.25 – $1.90
Volume
39,045
Avg volume (3m)
395,012
Mean target
$1.66
Low
$1.30
High
$2.06
Analysts
3
Consensus
STRONG BUY
RSI (14)
29.8
vs 50-day MA
-36.90%
1-mo return
-35.37%
3-mo return
-36.90%
Volume z-score
1.35

Saluda Medical, Inc., a medical device company, develops treatments for chronic neurological conditions in the United States, Australia, Europe, and internationally.

Sector: Healthcare · Industry: Medical Devices · United States · Website

Browse: all ASX stocks · Health Care picks · today's movers

General information only (Australia). This is general information, not financial product advice. It doesn't consider your objectives, financial situation or needs — consider its appropriateness and seek licensed advice before acting. Not a recommendation to buy or sell any financial product.

Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.